Literature summary for 2.1.2.2 extracted from

Cheng, H.; Hwang, I.; Chong, Y.; Tavassoli, A.; Webb, M.E.; Zhang, Y.; Wilson, I.A.; Benkovic, S.J.; Boger, D.L.
Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway (2005), Bioorg. Med. Chem., 13, 3593-3599.

Search for more literature for 2.1.2.2

Inhibitors

Inhibitors	Comment	Organism	Structure
additional information	no inhibition by N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid	Escherichia coli
N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid	effective inhibitor	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Escherichia coli	-	-	-
Homo sapiens	-	recombinant	-

Synonyms

Synonyms	Comment	Organism
GAR TFase	-	Escherichia coli
GAR TFase	-	Homo sapiens
glycinamide ribonucleotide transformylase	-	Escherichia coli
glycinamide ribonucleotide transformylase	-	Homo sapiens

Ki Value [mM]

Ki Value [mM]	Ki Value maximum [mM]	Inhibitor	Comment	Organism	Structure
0.0005	-	N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid	26°C, pH 7.5	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)